Episode 6: ABOG MOC Article: Myfembree Article Review :Starving endometriosis without weakenning the bone ?

This clinical study investigates the effectiveness and safety of treating endometriosis-associated pain with a combination of elagolix and hormonal add-back therapy. Researchers conducted a twelve-month trial to determine if adding low doses of estradiol and norethindrone could reduce the bone density loss typically caused by elagolix alone. The results demonstrate that this combination significantly improves menstrual and pelvic pain while remaining generally well-tolerated by patients. Most importantly, the research shows that add-back therapy successfully protects bone mineral density, keeping losses under one percent over a full year. These findings suggest that the combined treatment offers a viable long-term management strategy for women suffering from chronic endometriosis symptoms. Therefore, the study concludes that adding hormones allows for extended use of the medication without compromising its pain-relieving benefits.